Efficacy/Safety of Imprime PGG With Cetuximab & Paclitaxel/Carboplatin Therapy in Pts With Untreated Advanced Non-Small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

August 31, 2009

Primary Completion Date

November 30, 2012

Study Completion Date

August 31, 2015

Conditions
NSCLC
Interventions
BIOLOGICAL

Imprime PGG Injection

4 mg/kg i.v. over 2 hrs, weekly, in three week cycles

BIOLOGICAL

Cetuximab

initial loading dose of 400 mg/m\^2 over 120 min and subsequent doses at 250 mg/m\^2 over 60 min, weekly on Days 1, 8 and 15 of each 3-week treatment cycle

DRUG

Paclitaxel

200 mg/m\^2 i.v. over 3 hr on Day 2 of each 3-week treatment cycle for the first 4 to 6 treatment cycles

DRUG

Carboplatin

dose equal to an AUC of 6 mg/mL · min based on the Calvert formula; i.v. over 30 min on Day 2 of each 3-week treatment cycle for the first 4 to 6 treatment cycles

Trial Locations (14)

30912

Medical College of Georgia, Augusta

37075

Georg-August University Gottingen, Göttingen

42283

HELIOS Klinikum Wuppertal, Medizinische Klinik 1, Wuppertal

47802

Providence Medical Group, Terre Haute

55455

University of Minnesota, Minneapolis

75201

Mary Crowley Medical Research Center, Dallas

79701

Allison Cancer Center, Midland

89081

Universitätsklinikum Ulm, Ulm

Unknown

Helios Clinic Emil von Behring, Berlin

Municipal Clinic Frankfurt Hoescht, Frankfurt

University Clinical Heidelberg, Heidelberg

Clinic Minden, Minden

Techincal University of Munich, Munich

Clinic Nurnberg Nord, Nuremberg

Sponsors

Lead Sponsor

All Listed Sponsors
lead

HiberCell, Inc.

INDUSTRY

NCT00874848 - Efficacy/Safety of Imprime PGG With Cetuximab & Paclitaxel/Carboplatin Therapy in Pts With Untreated Advanced Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter